Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
13426327 | Schizophrenia Research | 2019 | 5 Pages |
Abstract
We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (nâ¯=â¯50 PP; nâ¯=â¯1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6â¯months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Brian J. Miller, Amy Claxton, Yangchun Du, Peter J. Weiden, Steven G. Potkin,